646: OUTCOMES OF CRE INFECTIONS IN IMMUNOCOMPROMISED HOSTS: AN ANALYSIS OF THE CARE STUDY.
- Resource Type
- Article
- Authors
- Komirenko, Allison; Cebrik, Deborah; Smith, Alex; Hou, Audrey; Satlin, Michael
- Source
- Critical Care Medicine. 2019 Supplement, Vol. 47, p303-303. 1p.
- Subject
- *IMMUNOCOMPROMISED patients
*URINARY tract infections
- Language
- ISSN
- 0090-3493
B Learning Objectives: b Immunocompromised patients are susceptible to serious infections, including those caused by carbapenem-resistant Enterobacteriaceae (CRE). One patient randomized to plazomicin and 1 patient randomized to colistin did not qualify for the modified microbiological intent-to-treat (mMITT) population (requiring confirmed baseline CRE). B Conclusions: b In a subgroup of immunocompromised patients from the CARE study, lower rates of ACM or SDRCs and nephrotoxicity were observed with plazomicin-based therapy vs colistin-based therapy. [Extracted from the article]